New insider Dhaliwal Harpreet S. claimed ownership of 36,083 shares (SEC Form 3)
$PCVX
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 04/17/2025 |
3. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock | 36,083 | D(1) | |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Stock Option (right to buy) | (2) | 11/07/2031 | Common Stock | 96,010 | $25.06 | D | |
| Stock Option (right to buy) | (3) | 03/01/2032 | Common Stock | 45,000 | $24.79 | D | |
| Stock Option (right to buy) | (4) | 12/30/2032 | Common Stock | 15,000 | $47.95 | D | |
| Stock Option (right to buy) | (5) | 03/01/2033 | Common Stock | 62,143 | $41.67 | D | |
| Stock Option (right to buy) | (6) | 02/28/2034 | Common Stock | 30,000 | $73.82 | D | |
| Performance Stock Option (right to buy) | (7) | 11/06/2034 | Common Stock | 28,907 | $102.7 | D | |
| Performance Restricted Stock Units | (8) | 11/06/2034 | Common Stock | 11,783 | $0 | D | |
| Stock Option (right to buy) | (9) | 02/26/2035 | Common Stock | 44,903 | $74.22 | D | |
| Explanation of Responses: |
| 1. This amount includes 23,584 restricted stock units ("RSUs") that, upon vesting, will be settled in shares of the Issuer's Common Stock on a 1-for-1 basis. The RSUs were granted in four tranches: On March 2, 2022; March 1, 2023; February 29, 2024; and February 27, 2025. The RSUs vest(ed) as to 25% of the shares subject to the award at the first sixth-months following grant, and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. |
| 2. 1/4 of shares subject to the option vested on October 1, 2022, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. |
| 3. 1/48 of shares subject to the option vested on April 2, 2022, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. |
| 4. 1/48 of shares subject to the option vested on January 30, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. |
| 5. 1/48 of shares subject to the option vested on April 1, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. |
| 6. 1/48 of shares subject to the option vested on March 31, 2024, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. |
| 7. As part of a company-wide grant to all eligible employees of the Issuer, on November 7, 2024 (the "Grant Date"), the Reporting Person was granted a performance stock option to purchase 28,907 shares of the Issuer's Common Stock at a per share exercise price of $102.70. The option is subject to (1) a service-based vesting condition (vesting as to one-third of the shares on each of the third, fourth and fifth anniversaries of the Grant Date) and (2) a performance-vesting condition (which generally requires that the trading price of the Issuer's Common Stock average, over a one-year period, is at least $154.05 (150% of the Grant Date closing price)). |
| 8. Represents the target number of shares of Issuer's Common Stock underlying an award of performance restricted stock units ("PSUs"). Each PSU represents the contingent right to receive one share of the Issuer's Common Stock. The attainment of the performance vesting condition will be based on the Issuer's percentile rank within a peer group based on total shareholder return ("TSR") during a four-year performance period that commenced on November 7, 2024, the Grant Date, subject to the Reporting Person's continuous service with the Issuer through completion of the performance period. The actual number of shares of the Issuer's Common Stock deliverable with respect to the award varies based on performance and ranges from 0% to 250% of the target number of shares. |
| 9. 1/48 of shares subject to the option vested on March 27, 2025, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. |
| Remarks: |
| Harpreet S. Dhaliwal, by /s/ Peter N. Efremenko, Attorney-In-Fact | 04/25/2025 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||